|
|
|
|
Monday, March 9, 2020
PDS Biotechnology (PDSB)
Overcoming Limitations of Cancer Vaccines
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is primarily engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.
Cosme Ordonez, Senior Research Analyst, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
We are initiating coverage of PDS Biotechnology.
PDS Biotechnology is developing a platform technology known as Versamune for the treatment of cancer. Versamune consists of cationic (positively charged) lipids mix with tumor or viral antigens. Cationic lipids act as a vehicle to deliver the antigens to dendritic cells, which mature and help inducing a potent T-cell driven anti-cancer immune response.
The Company’s lead product is Versamune-HPV, which is currently in Phase II clinical trials for the treatment of human cancers associated with infection by human papillomavirus (HPV). PDS Biotechnology is collaborating with Merck & Co., and the National Cancer Institute (NCI) to fund and advance its clinical programs. Based on our analysis of existing preclinical and clinical data, we believe…
Get the full report on Channelchek desktop.
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst
certification and important disclosures included in the full report.
NOTE: investment decisions should not be based upon the content of
this research summary. Proper due diligence is required before
making any investment decision.